Biovica, a company specializing in blood-based cancer monitoring, today announced that new results involving DiviTum® TKa have been published in the peer-reviewed journal Clinical Cancer Research.
The study evaluated a new treatment combination for patients with advanced breast cancer whose disease had progressed after previous CDK4/6 inhibitor treatment. The combination included avutometinib, a drug targeting a pathway linked to resistance to CDK4/6 inhibitors, together with abemaciclib and fulvestrant.
Importantly, all patients who experienced clinical benefit had low TKa levels early during treatment, while higher levels were seen in patients who did not benefit.
These findings support the potential of DiviTum TKa to identify treatment benefit early, an important step toward its future use in treatment decisions and clinical drug development.
“This publication provides a clear example of how DiviTum TKa may offer clinically relevant information early during treatment. For Biovica, the results strengthen the scientific foundation for expanding the use of DiviTum TKa across new treatment classes and clinical studies, while further supporting the relevance of our Pharma Services offering” said Theis Kipling, CEO of Biovica.
The study included 16 patients, and the TKa results were exploratory. An ongoing Phase II study will further evaluate TKa alongside other biomarkers, providing an opportunity to validate and build on these results.
The article, titled Avutometinib, Abemaciclib, and Fulvestrant in Patients with HR+/HER2- Metastatic Breast Cancer Previously Treated with CDK4/6 Inhibitor: A Single-Arm Phase I Trial, was published in Clinical Cancer Research.